Supply Chain Intelligence
Contract Development & Manufacturing
Real-time intelligence, expert analysis, and verified research for the Contract Development & Manufacturing industry. Stay ahead in 3 minutes a day.
Stay ahead of Contract Development & Manufacturing in 3 minutes a day.
Expert-verified intelligence delivered to your inbox every morning.
Free forever. No spam. Unsubscribe anytime.
Novartis terminates $64M plant contract with Chinese CDMO Porton
Swiss pharma giant ends Slovenia facility lease with Porton Pharma over regulatory disputes, threatening legal action.
Read full articleBoryung expands global CDMO business with Taiwan's Lotus deal
Korean pharma begins Alimta cancer drug supply to Lotus, marking major expansion in cytotoxic drug manufacturing.
Read full articleBrazil plans $1.2B vaccine complex PPP, Latin America's largest
Federal government structures massive public-private partnership for Bio-Manguinhos/Fiocruz facility in Rio.
Read full articleWest Pharma fully recovers from May cyberattack, operations restored
Medical device manufacturer resumes global operations after data theft incident, expects no material impact.
Read full articleBIOSECURE Act drives pharma supply chain shift away from China
Novartis-Porton dispute signals major realignment as companies de-risk China partnerships amid new regulations.
Read full articleGlobal cytotoxic drug shortages drive CDMO expansion opportunities
Production stoppages and supply chain issues create urgent demand for specialized cancer drug manufacturers.
Read full articlePorton faces major losses as Novartis dispute threatens operations
Chinese CDMO warns of material adverse impact after investing $65.8M in now-disputed Slovenia facility.
Read full articleBrazil's vaccine PPP to quadruple Bio-Manguinhos production capacity
New complex will produce 120 million vials annually, becoming Latin America's largest biopharmaceutical center.
Read full articleNovartis terminates $64M plant contract with Chinese CDMO Porton
Swiss pharma giant ends Slovenia facility lease with Porton Pharma over regulatory disputes, threatening legal action.
Read full articleBoryung expands global CDMO business with Taiwan's Lotus deal
Korean pharma begins Alimta cancer drug supply to Lotus, marking major expansion in cytotoxic drug manufacturing.
Read full articleBrazil plans $1.2B vaccine complex PPP, Latin America's largest
Federal government structures massive public-private partnership for Bio-Manguinhos/Fiocruz facility in Rio.
Read full articleWest Pharma fully recovers from May cyberattack, operations restored
Medical device manufacturer resumes global operations after data theft incident, expects no material impact.
Read full articleBIOSECURE Act drives pharma supply chain shift away from China
Novartis-Porton dispute signals major realignment as companies de-risk China partnerships amid new regulations.
Read full articleGlobal cytotoxic drug shortages drive CDMO expansion opportunities
Production stoppages and supply chain issues create urgent demand for specialized cancer drug manufacturers.
Read full articlePorton faces major losses as Novartis dispute threatens operations
Chinese CDMO warns of material adverse impact after investing $65.8M in now-disputed Slovenia facility.
Read full articleBrazil's vaccine PPP to quadruple Bio-Manguinhos production capacity
New complex will produce 120 million vials annually, becoming Latin America's largest biopharmaceutical center.
Read full articleStay ahead of Contract Development & Manufacturing in 3 minutes a day.
Live opportunity intelligence for your market, delivered to your inbox every morning. Read it over coffee.
Free forever. No spam. Unsubscribe anytime.